devdiscourse55m
Novo Holdings Acquires Catalent: A Deal to Boost Weight-Loss Drug Production
Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...
Hosted on MSN3h
Manhattan Corp, Novo Resources team up to probe Tibooburra for gold
Nanocap and highly illiquid explorer Manhattan Corporation (ASX:MHC) has struck a farm-in deal with Novo Resources (ASX:NVO) ...
devdiscourse6h
Health Headlines: Legal Battles, Breakthroughs, and Controversies Unveiled
Catalent's acquisition by Novo Holdings faces regulatory updates. UK sees a preference for Mounjaro over Wegovy. This image ...
ENDPOINTS NEWS8h
FTC OKs No­vo-Catal­ent deal in ma­jor win for No­vo Nordisk’s GLP-1 man­u­fac­tur­ing
FTC approves Novo Holdings' $16.5B Catalent acquisition. Deal includes selling 3 facilities to Novo Nordisk for $11B, despite ...
Pharmaceutical Technology13h
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 ...